查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466438

隱球菌病市場：依治療方法、通路分類 - 全球預測 2024-2030

Cryptococcosis Market by Treatment (Amphotericin B, Fluconazole, Flucytosine), Distribution Channel (Hospital Pharmacies, Mail Order Pharmacies, Retail Pharmacies & Drug Stores) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年隱球菌病市場規模為59.1億美元，預計2024年將達63.5億美元，2030年將達到99億美元，複合年成長率為7.64%。

隱球菌病市場包括涉及隱球菌病預防、診斷、治療和管理的各種藥物、服務和活動。這包括行銷專門用於治療隱球菌病的抗真菌藥物，隱球菌病是一種由隱球菌屬引起的真菌感染疾病，主要影響肺部和中樞神經系統。隱球菌病市場的主要應用是藥物治療和診斷測試。愛滋病毒/愛滋病和其他削弱免疫力的疾病的增加是推動隱球菌病治療藥物需求的主要因素。診斷技術的進步使得能夠及早、準確地識別感染疾病，增加了對治療藥物的需求。世界各地（尤其是新興國家）醫療保健基礎設施的擴張也支持了市場開拓。新興經濟體開拓的市場以及抗真菌抗藥性管理和個人化醫療方法的進一步開拓存在潛在機會。儘管存在這些成長要素，但抗真菌治療的高昂費用限制了一些患者獲得治療的機會。人們越來越擔心抗真菌抗藥性會降低現有治療方法的有效性。此外，一些地區的醫療基礎設施薄弱可能會阻礙先進治療和診斷的引入。藥物核准的監管障礙和新型抗真菌化合物的管道有限也影響了市場潛力。新型藥物輸送系統（例如奈米顆粒和標靶藥物輸送）的進步有可能顯著提高現有治療方法的療效。替代療法（例如免疫療法和聯合治療）的研究也可能導致這種疾病的治療取得突破。最後，開發快速、靈敏且具成本效益的診斷測試對於早期發現和早期治療至關重要。

主要市場統計
基準年[2023] 59.1億美元
預測年份 [2024] 63.5億美元
預測年份 [2030] 99億美元
複合年成長率（%） 7.64%

治療Amphotericin B主要用於治療顯著的隱球菌病病例。

Amphotericin B是一種強效抗真菌藥物，常被用作重症隱球菌病、尤其是隱球菌腦膜炎的第一線治療藥物。由於口服生物利用度較低，通常靜脈注射。Amphotericin B與麥角固醇（真菌細胞膜的主要成分）結合，形成孔洞並殺死細胞。然而，嚴重的副作用，如腎毒性（腎損傷）、發燒、發冷和貧血可能會限制其使用，並且在治療期間必須進行監測。Fluconazole是一種三唑類抗真菌藥物，用於治療各種型態的隱球菌感染疾病並作為預防疾病復發的維持治療。這是一種有利的治療選擇，因為它可以口服給藥並且具有良好的安全性。Fluconazole透過抑制真菌細胞色素 P450 酶羊毛甾醇 14-a-脫甲基酶（麥角甾醇合成所需）來發揮作用，從而抑制真菌細胞膜的合成。儘管Fluconazole有效，但它可能會產生抗藥性，尤其是長期使用。Flucytosine又稱5-氟胞嘧啶，是抗真菌藥物，由於其協同效應，常與Amphotericin B聯合用於治療隱球菌病。該藥物在真菌細胞中轉化為 5-Fluorouracil，抑制 DNA 和 RNA 合成並導致細胞死亡。儘管Flucytosine通常耐受性良好，但它具有骨髓抑制和胃腸道不適等副作用。由於可能會產生對Flucytosine的抗藥性，因此其使用通常僅限於在仔細的醫療監督下聯合治療。

通路零售藥局是輕鬆快速取得隱球菌病藥物的好選擇。

隱球菌病藥物透過多種管道分發，以確保患者能夠獲得。醫院藥局是隱球菌病藥物的主要通路。住院患者通常在這裡接受初步治療，尤其是感染疾病嚴重的患者。醫院藥局維持重要抗真菌藥物（如Amphotericin B和Flucytosine）的供應，並確保及時給藥，作為醫院護理的一部分。這些設施對於急性管理和在門診環境中啟動持續治療方法至關重要。通訊藥局為出院後治療隱球菌病的患者或正在進行長期治療計劃的患者提供了一種方便且通常節省成本的方法。這種通路有利於需要穩定藥物供應的患者，並增加了送貨上門的便利性。通訊服務對於居住在偏遠地區或行動不便的患者尤其有利。零售藥局和藥局是購買門診病人藥物的便利場所。這些商店對於需要快速處方箋和續藥的患者至關重要，並且它們提供廣泛的地理覆蓋範圍和延長的營業時間。零售藥局也提供藥事服務和諮詢，並在整體疾病管理中發揮重要作用。

區域洞察

在美洲，特別是在美國和加拿大，隱球菌病被認為是一種機會性感染疾病，主要影響免疫力缺乏，例如愛滋病毒/愛滋病患者。儘管廣泛的抗逆轉濾病毒治療計劃已經降低了隱球菌病的發生率，但它仍然是一個令人擔憂的問題。這些國家的客戶購買行為傾向於青睞經過 FDA 批准且具有良好有效性記錄的既定治療方法。用於研究隱球菌腦膜炎的研究津貼投入增加，並且重點放在改進診斷技術上。在歐盟國家，消費者對隱球菌病治療的需求很大程度取決於免疫力缺乏患者群體的病例。歐盟遵循影響購買行為的嚴格監管準則，並且經證明不僅有效而且具有成本效益的產品通常會受到青睞。歐盟最近的計劃，例如創新藥物計劃，支持新治療方法的研究。中東和非洲地區隱球菌病的發生率差異很大，撒哈拉以南非洲地區的愛滋病毒/愛滋病發病率特別高，造成了重大負擔。非洲市場正在尋找負擔得起且容易獲得的治療方法，而富裕的中東國家正在轉向更新、更先進的治療方法。非洲針對愛滋病毒/愛滋病的公共衛生努力也在隱球菌病的管理中發揮重要作用。在亞太地區，中國、日本和印度等國家呈現多樣化的市場動態。亞太地區的抗真菌藥物專利也在增加，當地製藥公司尋求滿足該地區的需求。

FPNV定位矩陣

FPNV定位矩陣對於評估隱球菌病市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對隱球菌病市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1. 隱球菌病市場的市場規模和預測是多少？

2.在隱球菌病市場預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.隱球菌市場的技術趨勢和法規結構是什麼？

4.隱球菌病市場主要供應商的市場佔有率是多少？

5. 進入隱球菌市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和致命真菌病的盛行率增加
      • 與愛滋病毒/愛滋病隱球菌病相關的新發現
      • 提高學名藥和成藥的供應
    • 抑制因素
      • 患者臨床治療意識的局限性
      • 由於感染患者死亡率增加，檢測和診斷範圍縮小
    • 機會
      • 政府首選計劃開發隱球菌腦膜炎的有效治療方法
      • 隱球菌病藥物開發的增加和臨床試驗生態系統的演變
    • 任務
      • 與使用隱球菌病藥物相關的副作用
      • 由於製藥公司無法滿足需求，藥物開發計畫資金不足
  • 市場區隔分析
    • 治療：Amphotericin B主要用於治療嚴重的隱球菌病病例。
    • 分銷管道：零售藥局是輕鬆快速取得隱球菌病藥物的好選擇。
  • 市場趨勢分析
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析
  • 客戶客製化

第6章 隱球菌病市場（依治療）

  • 兩性黴素B
  • Fluconazole
  • Flucytosine

第7章 隱球菌病市場：按分銷管道

  • 醫院藥房
  • 通訊藥房
  • 零售藥局/藥局

第8章美洲隱球菌病市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區隱球菌病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲的隱球菌病市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Astellas來製藥完成對 Propeller Therapeutics 的收購
    • 諾華透過收購 DTx Pharma 加強神經科學產品線和 xRNA 平台能力
    • 葛蘭素史克同意收購後期生物製藥公司 BELLUS Health

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4348D129F9A0

[183 Pages Report] The Cryptococcosis Market size was estimated at USD 5.91 billion in 2023 and expected to reach USD 6.35 billion in 2024, at a CAGR 7.64% to reach USD 9.90 billion by 2030.

The Cryptococcosis market encompasses a range of pharmaceutical products, services, and activities involved in the prevention, diagnosis, treatment, and management of Cryptococcosis. It includes the sales of antifungal drugs specifically used to treat Cryptococcosis, a fungal infection caused by Cryptococcus species, which primarily affects the lungs and central nervous system. The primary applications of the Cryptococcosis market involve pharmaceutical therapies and diagnostic testing. An increasing rate of HIV/AIDS and other conditions leading to compromised immune systems contribute significantly to generating need for the Cryptococcosis medication. Advancements in diagnostic technologies allow for early and precise identification of the infection, thus propelling the demand for treatments. Expansion in healthcare infrastructure globally, especially in the developing countries, also foster's market growth. Potential opportunities exist in the untapped markets of emerging economies and in the further development of antifungal resistance management and personalized medicine approaches. Despite the growth factors, high costs associated with antifungal therapy can limit accessibility for some patients; there is also a growing concern over antifungal resistance which reduces the efficacy of existing treatments. Furthermore, poor healthcare infrastructure in some regions can impede the adoption of advanced therapeutics and diagnostics. Regulatory hurdles for drug approval and the limited pipeline of novel antifungal compounds also affect market potential. Advances in novel drug delivery systems, such as nanoparticle and targeted drug delivery, could greatly improve the efficacy of existing treatments. Research into alternative treatments, such as immunotherapies or combination therapies, could also offer breakthroughs in the management of the disease. Lastly, the development of rapid, sensitive, and cost-effective diagnostic tests is essential for early detection and treatment.

KEY MARKET STATISTICS
Base Year [2023] USD 5.91 billion
Estimated Year [2024] USD 6.35 billion
Forecast Year [2030] USD 9.90 billion
CAGR (%) 7.64%

Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis

Amphotericin B is a powerful antifungal medication often used as a primary treatment for severe cases of cryptococcosis, particularly cryptococcal meningitis. It is typically administered intravenously due to its poor oral bioavailability. Amphotericin B binds to ergosterol, a key component of fungal cell membranes, creating pores that lead to the cell's death. However, its use can be limited by significant side effects including nephrotoxicity (kidney damage), fever, chills, and anemia, therefore, monitoring is necessary during treatment. Fluconazole is a triazole antifungal medication used as a treatment for various forms of cryptococcal infections and as maintenance therapy to prevent recurrence of the disease. It is an advantageous treatment option due to its oral administration and favorable safety profile. Fluconazole works by inhibiting the fungal cytochrome P450 enzyme lanosterol 14-a-demethylase, which is required for the synthesis of ergosterol, thus disrupting fungal cell membrane synthesis. Despite its effectiveness, fluconazole resistance can occur, especially with prolonged use. Flucytosine, also known as 5-fluorocytosine, is an antifungal medication that is often used in combination with Amphotericin B for the treatment of cryptococcosis due to its synergistic effects. The drug is converted within fungal cells into 5-fluorouracil, which inhibits DNA and RNA synthesis, leading to cell death. Flucytosine is generally well-tolerated but can have side effects such as bone marrow suppression and gastrointestinal upset. Resistance to flucytosine can develop, and thus its use is typically reserved for combination therapy under careful medical supervision.

Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications

Cryptococcosis medications are distributed through various channels to ensure availability for patients. Hospital pharmacies represent a principal distribution channel for cryptococcosis medications. Hospitalized patients often receive their initial treatment in this setting, particularly if the infection is severe. Hospital pharmacies maintain a supply of crucial antifungals such as Amphotericin B and Flucytosine and ensure timely administration as part of inpatient care. These facilities are essential for acute management and for initiating treatment regimens that may be continued on an outpatient basis. Mail order pharmacies offer a convenient and often cost-saving avenue for patients managing cryptococcosis post-discharge or for those under long-term treatment plans. This distribution channel is beneficial for patients requiring consistent medication supplies with the added convenience of home delivery. Mail order services can be particularly advantageous for those living in remote areas or for patients with limited mobility. Retail pharmacies and drug stores serve as an accessible point of purchase for outpatient cryptococcosis medications. These establishments are crucial for patients who may need to fill or refill prescriptions rapidly, offering widespread geographic coverage and extended operating hours. Retail pharmacies also provide pharmaceutical care and counsel, playing a significant role in the overall management of the condition.

Regional Insights

In the Americas, particularly in the United States and Canada, cryptococcosis is considered an opportunistic infection predominantly affecting immunocompromised individuals, such as those with HIV/AIDS. Large-scale antiretroviral treatment programs have helped reduce the incidence of cryptococcosis, but it remains a concern. Customer purchasing behavior in these nations tends to prioritize well-established, FDA-approved treatments with a proven track record of efficacy. There has been an increase in investment towards research grants for studying cryptococcal meningitis, as well as a focus on improved diagnostic techniques. In EU countries, the consumer need for cryptococcosis treatments is largely driven by cases among immunocompromised patient populations. The EU follows stringent regulatory guidelines which influence purchasing behavior, often favoring products that have demonstrated not only efficacy but also cost-effectiveness. Recent EU initiatives, such as the Innovative Medicines Initiative, have supported research into new treatments. The MEA region exhibits a wide disparity in the incidence of cryptococcosis, with Sub-Saharan Africa bearing a significant burden due to high rates of HIV/AIDS. There is a clear need for affordable and accessible treatments within African markets, while wealthier Middle Eastern nations may focus on newer and more advanced therapy options. Public health initiatives aimed at HIV/AIDS in Africa also play a crucial role in the management of cryptococcosis. In the Asia Pacific, countries such as China, Japan, and India present diverse market dynamics. The Asia Pacific region is also seeing an uptick in patents related to antifungal medications, driven by local pharmaceutical companies seeking to address the regional needs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cryptococcosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cryptococcosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cryptococcosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., B.M. Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb Company, Citron Pharma, Eisai Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Jolly Limited, Lunan Pharmaceutical Group, Matinas Biopharma Holdings, Inc., Merck & Co., Inc., Novartis AG, NuCare Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Sigmapharm Laboratories, LLC, Skyepharma Production SAS, Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cryptococcosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Amphotericin B
    • Fluconazole
    • Flucytosine
  • Distribution Channel
    • Hospital Pharmacies
    • Mail Order Pharmacies
    • Retail Pharmacies & Drug Stores
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cryptococcosis Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cryptococcosis Market?

3. What are the technology trends and regulatory frameworks in the Cryptococcosis Market?

4. What is the market share of the leading vendors in the Cryptococcosis Market?

5. Which modes and strategic moves are suitable for entering the Cryptococcosis Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Prevalence of Infectious Diseases and Fatal Fungal Disease
      • 5.1.1.2. Rising Insights into HIV/AIDS-Associated Cryptococcosis
      • 5.1.1.3. Increasing Availability of Generic and Over-the-Counter Medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Clinical Awareness in Patients Regarding Treatments
      • 5.1.2.2. Reduced Scope of Testing and Diagnostics due to Increased Mortality Among Cryptococcosis Infected Patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable Government Programs for the Development of Effective Therapeutics for Cryptococcal Meningitis Disease
      • 5.1.3.2. Increasing Drug Development and Evolving Clinical Trial Ecosystem for Cryptococcosis
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects Associated with The Usage of Cryptococcosis Drugs
      • 5.1.4.2. Pharmaceutical Companies Failing to Address The Need and Poorly Funded Drug Development Programs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Amphotericin B primarily and significantly used to treat the vital cases of cryptococcosis
    • 5.2.2. Distribution Channel: Retail pharmacies are good option for easy and quick availability of cryptococcosis medications
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Cryptococcosis Market, by Treatment

  • 6.1. Introduction
  • 6.2. Amphotericin B
  • 6.3. Fluconazole
  • 6.4. Flucytosine

7. Cryptococcosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Mail Order Pharmacies
  • 7.4. Retail Pharmacies & Drug Stores

8. Americas Cryptococcosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cryptococcosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cryptococcosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Astellas Completes Acquisition of Propella Therapeutics
    • 11.3.2. Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma
    • 11.3.3. GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company BELLUS Health

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CRYPTOCOCCOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. CRYPTOCOCCOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CRYPTOCOCCOSIS MARKET DYNAMICS
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. ARGENTINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 35. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. BRAZIL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 39. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. CANADA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 43. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. MEXICO CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 50. UNITED STATES CRYPTOCOCCOSIS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 60. AUSTRALIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. CHINA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 67. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. INDIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. INDONESIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 75. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. JAPAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MALAYSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. PHILIPPINES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. SINGAPORE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. SOUTH KOREA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 95. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. TAIWAN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 99. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. THAILAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 103. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. VIETNAM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 113. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. DENMARK CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 117. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. EGYPT CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. FINLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 125. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. FRANCE CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. GERMANY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 133. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. ISRAEL CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 137. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ITALY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. NETHERLANDS CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 145. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. NIGERIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. NORWAY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 153. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. POLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 157. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. QATAR CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 161. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. RUSSIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 173. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SPAIN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 177. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SWEDEN CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. SWITZERLAND CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 185. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TURKEY CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CRYPTOCOCCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. CRYPTOCOCCOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CRYPTOCOCCOSIS MARKET, FPNV POSITIONING MATRIX, 2023